Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Debt / NOTE 2.500% 3/1
-
Market price (% of par)
-
121.05%
-
Total 13F principal
-
$23,000,000
-
Principal change
-
+$6,000,000
-
Total reported market value
-
$27,841,500
-
Number of holders
-
1
-
Value change
-
+$7,263,000
-
Number of buys
-
1
Institutional Holders of BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1 as of Q4 2023
As of 31 Dec 2023,
BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1 was held by
1 institutional
bondholder
reporting positions in Form 13F filings.
These institutions reported holding
$23,000,000
in principal (par value) of the bond.
The largest 10 bondholders included
BRAIDWELL LP, Graham Capital Management, L.P., ARISTEIA CAPITAL, L.L.C., LINDEN ADVISORS LP, ADVENT CAPITAL MANAGEMENT /DE/, Voya Investment Management LLC, D. E. Shaw & Co., Inc., Point72 Asset Management, L.P., WELLS FARGO & COMPANY/MN, and Affinity Asset Advisors, LLC.
This page lists
43
institutional bondholders reporting positions
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.